Short answer
Denali Therapeutics Inc. (DNLI) filed an 8-K current report with the SEC on June 18, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 7.01 (Regulation FD Disclosure). $195 million cash proceeds upon closing from sale of FDA Rare Pediatric Disease Priority Review Voucher.
Denali Therapeutics Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- $195 million cash proceeds upon closing from sale of FDA Rare Pediatric Disease Priority Review Voucher
- Voucher awarded after AVLAYAH approval for Hunter syndrome in March 2026
- Closing subject to customary conditions, including Hart-Scott-Rodino antitrust waiting-period clearance
- Agreement includes customary representations, covenants, and indemnification provisions with limitations
Item 7.01 · Regulation FD Disclosure
- Denali issued a June 18, 2026 press release under Regulation FD, making material information broadly available
- Full disclosure details appear in Exhibit 99.1, which investors should review for the event’s financial or clinical implications
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Denali Therapeutics Inc. 8-K filings
Get the next DNLI 8-K as it lands
Follow DNLI for push alerts, or ask the research agent what this filing means.